Sumitomo Mitsui Trust Group Inc. Boosts Stake in Compass Pathways PLC Sponsored ADR $CMPS

Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 49.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 368,828 shares of the company’s stock after acquiring an additional 121,491 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Compass Pathways were worth $2,040,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CMPS. Toronto Dominion Bank lifted its holdings in Compass Pathways by 152.9% in the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after acquiring an additional 1,529,013 shares during the period. Nantahala Capital Management LLC grew its stake in shares of Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after purchasing an additional 1,350,698 shares during the period. Ameriprise Financial Inc. acquired a new position in shares of Compass Pathways during the 3rd quarter worth $6,926,000. Siren L.L.C. purchased a new position in shares of Compass Pathways in the 4th quarter valued at about $6,900,000. Finally, Two Sigma Investments LP lifted its stake in shares of Compass Pathways by 838.4% in the third quarter. Two Sigma Investments LP now owns 1,075,277 shares of the company’s stock valued at $6,161,000 after purchasing an additional 960,685 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on CMPS shares. UBS Group set a $18.00 price objective on shares of Compass Pathways in a report on Thursday, May 7th. Compass Point set a $25.00 price target on shares of Compass Pathways in a research report on Tuesday, July 7th. Oppenheimer reissued an “outperform” rating and set a $20.00 price target on shares of Compass Pathways in a research note on Tuesday, July 7th. Maxim Group upped their price target on Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Finally, Royal Bank Of Canada raised their price objective on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Compass Pathways has a consensus rating of “Moderate Buy” and a consensus price target of $24.15.

Compass Pathways Stock Performance

NASDAQ:CMPS opened at $13.31 on Thursday. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.80 billion, a P/E ratio of -4.23 and a beta of 2.47. The firm has a 50-day moving average price of $12.24 and a two-hundred day moving average price of $8.77. Compass Pathways PLC Sponsored ADR has a twelve month low of $3.50 and a twelve month high of $15.40.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. As a group, research analysts expect that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.